CD34 and acute myeloid leukemia: To validate FEV expression in AML, BM aspirates from 53 primary AML patients were examined using reverse transcription-polymerase chain reaction (RT–PCR), and BM mononuclear cells (MNCs) and CD34+ cells from healthy donors were also examined as controls.